Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.

Autor:	Peres LC; Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Oswald LB; Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Dillard CM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., De Avila G; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Nishihori T; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Blue BJ; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Freeman CL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Locke FL; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Alsina M; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Castaneda Puglianini O; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS., Sborov DW; Division of Hematology and Hematologic Malignancies, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT., Wagner C; Division of Hematology and Hematologic Malignancies, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT., Dima D; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH., Hashmi H; Department of Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston, SC., Davis JA; Department of Pharmacy, Medical University of South Carolina, Charleston, SC., Kocoglu MH; Division of Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Badros AZ; Division of Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD., Atrash S; Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC., Simmons G; Cellular Immunotherapies and Transplant Program, Virginia Commonwealth University Massey Cancer Center, Richmond, VA., Kalariya N; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Ferreri C; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX., Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX., Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN., Liu L; City of Hope, Duarte, CA., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Voorhees P; Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC., Khouri J; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, OH., McGuirk J; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Kansas City, KS., Sidana S; Division of Bone Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA., Hansen DK; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Patel K; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2024 Jan 09; Vol. 8 (1), pp. 251-259.
DOI:	10.1182/bloodadvances.2023010894
Abstrakt:	Abstract: Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of standard of care (SOC) ide-cel in racially and ethnically diverse populations have been understudied. This study pooled data from 207 patients with RRMM (28% patients of racial and ethnic minority groups) treated with SOC ide-cel across 11 institutions to examine racial and ethnic differences in the incidence of toxicities and adverse events, response to ide-cel, and survival. This study included 22 (11%) Hispanic, 36 (17%) non-Hispanic Black, and 149 (72%) non-Hispanic White patients with RRMM. Compared with Hispanic and non-Hispanic White patients, non-Hispanic Black patients had higher median levels of C-reactive protein (1.0, 0.8, and 3.5 mg/dL, respectively; P = .02) and baseline ferritin (362.0 vs 307.0 vs 680.5, respectively; P = .08) and were more likely to develop cytokine release syndrome (77%, 85%, and 97%, respectively; P = .04). Although best overall response rate was lower among Hispanic patients (59%) than among non-Hispanic Black (86%) and White patients (86%; P = .01), there were no racial and ethnic differences in progression-free or overall survival. We provide, to our knowledge, the first and largest investigation of clinical outcomes of SOC ide-cel by race and ethnicity. Despite differences in safety and response to ide-cel, our findings encourage the use of ide-cel in all patients with RRMM. These findings should be confirmed in larger samples of diverse patients with RRMM, with longer follow-up time. (© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu